The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia

Comprehensive Psychiatry

Volumn 51, Issue 2, 2010, Pages 165-170

  Kim, Jong Hoon ^a   Ann, Jun Hyung ^a   Kim, Min Jung ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CORRELATION ANALYSIS; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SUBJECTIVE WELLBEING UNDER NEUROLEPTICS SCALE; SYMPTOM; WELLBEING;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DEPRESSION; FEMALE; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 75249100108     PISSN: 0010440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.comppsych.2009.05.004     Document Type: Article

References (65)

1. Zisook S., McAdams L.A., Kuck J., Harris M.J., Bailey A., Patterson T.L., et al. Depressive symptoms in schizophrenia. Am J Psychiatry 156 (1999) 1736-1743
2. Siris S.G. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry 157 (2000) 1379-1389
3. Koreen A.R., Siris S.G., Chakos M., Alvir J., Mayerhoff D., and Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatry 150 (1993) 1643-1648
4. Subotnik K.L., Nuechterlein K.H., Asarnow R.F., Fogelson D.L., Goldstein M.J., and Talovic S.A. Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness. Am J Psychiatry 154 (1997) 1551-1556
5. Wassink T.H., Flaum M., Nopoulos P., and Andreasen N.C. Prevalence of depressive symptoms early in the course of schizophrenia. Am J Psychiatry 156 (1999) 315-316
6. Siris S.G., and Bench C. Depression and schizophrenia. In: Hirsch S.R., and Weinberger D.R. (Eds). Schizophrenia (2003), Blackwell Publishing, Oxford 142-167
7. Azorin J.M. Long-term treatment of mood disorders in schizophrenia. Acta Psychiatr Scand Suppl 91 (1995) 20-23
8. Meltzer H.Y., and Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152 (1995) 183-190
9. Walker A.M., Lanza L.L., Arellano F., and Rothman K.J. Mortality in current and former users of clozapine. Epidemiology 8 (1998) 671-679
10. Tollefson G.D., Sanger T.M., Beasley C.M., and Tran P.V. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 43 (1998) 803-810
11. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., Lakshminarayanan M., et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20 (1999) 491-505
12. Huppert J.D., Weiss K.A., Lim R., Pratt S., and Smith T.E. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 51 (2001) 171-180
13. Sim K., Mahendran R., Siris S.G., Heckers S., and Chong S.A. Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res 129 (2004) 141-147
14. Hansson L. Determinants of quality of life in people with severe mental illness. Acta Psychiatr Scand Suppl 429 (2006) 46-50
15. Narvaez J.M., Twamley E.W., McKibbin C.L., Heaton R.K., and Patterson T.L. Subjective and objective quality of life in schizophrenia. Schizophr Res 98 (2008) 201-208
16. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 10 Suppl 3 (1995) 133-138
17. Karow A., and Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 162 (2002) 3-10
18. de Haan L., Weisfelt M., Dingemans P.M., Linszen D.H., and Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics Scale and the Subjective Deficit Syndrome Scale. Psychopharmacology 162 (2002) 24-28
19. Naber D., Riedel M., Klimke A., Vorbach E.U., Lambert M., Kühn K.U., et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 111 (2005) 106-115
20. Lambert M., and Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 18 Suppl 2 (2004) 5-17
21. Lambert M., Schimmelmann B.G., Naber D., Schacht A., Karow A., Wagner T., et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 67 (2006) 1690-1697
22. Sajatovic M., Rosch D.S., Sivec H.J., Sultana D., Smith D.A., Alamir S., et al. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 53 (2002) 1319-1321
23. Lambert M., Holzbach R., Moritz S., Postel N., Krausz M., and Naber D. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. Int Clin Psychopharmacol 18 (2003) 251-260
24. Hofer A., Rettenbacher M.A., Edlinger M., Kemmler G., Widschwendter C.G., and Fleischhacker W.W. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatr Scand 116 (2007) 354-361
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
26. Naber D., Moritz S., Lambert M., Pajonk F.G., Holzbach R., Mass R., et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 50 (2001) 79-88
27. Kluge M., Wehmeier P.M., Dittmann R.W., Langer F., Czekalla J., Lehmann M., et al. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 38 (2005) 6-12
28. de Haan L., Nimwegen L., Amelsvoort T., Dingemans P., and Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 41 (2008) 125-128
29. Karow A., Moritz S., Lambert M., Schoder S., and Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology 38 (2005) 320-326
30. Yoon J.S., Kook S.H., Lee H.Y., Lee C., and Paik I.H. The development of a Korean modification of the scale to measure Subjective Well-Being Under Neuroleptic Treatment (SWN). J Korean Neuropsychiatr Assoc 39 (2000) 987-998
31. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
32. Bell M.D., Lysaker P.H., Beam-Goulet J.L., Milstein R.M., and Lindenmayer J.P. Five-component model of schizophrenia: assessing the factorial invariance of the Positive and Negative Syndrome Scale. Psychiatry Res 52 (1994) 295-303
33. Whitehorn D., Brown J., Richard J., Rui Q., and Kopala L. Multiple dimensions of recovery in early psychosis. Int Rev Psychiatry 14 (2002) 273-283
34. Good K.P., Whitehorn D., Rui Q., Milliken H., and Kopala L.C. Olfactory identification deficits in first-episode psychosis may predict patients at risk for persistent negative and disorganized or cognitive symptoms. Am J Psychiatry 163 (2006) 932-933
35. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbauch J. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
36. Beck A.T. Depression: clinical, experimental, and theoretical aspects (1967), Harper & Row, New York
37. Hahn H.M., Yum T.H., Shin Y.W., Kim K.H., Yoon D.J., and Chung K.J. A standardization study of Beck Depression Inventory in Korea. J Korean Neuropsychiatr Assoc 25 (1986) 487-502
38. Hogan T.P., Awad A.G., and Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13 (1983) 177-183
39. Voruganti L., and Awad A.G. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology 171 (2004) 121-132
40. Inada T., Yagi G., and Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 57 (2002) 227-238
41. Kim J.H., Jung H.Y., Kang U.G., Jeong S.H., Ahn Y.M., Byun H.J., et al. Metric characteristics of the DIEPSS: a practical combined rating scale for drug-induced movement disorders. Mov Disord 17 (2002) 1354-1359
42. Inada T., Beasley Jr. C.M., Tanaka Y., and Walker D.J. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 18 (2003) 39-48
43. Kim J.H., Cho S.Y., Byun H.J., Kang U.G., Ahn Y.M., and Kim Y.S. Multidimensional sensory phenomena in antipsychotic-induced akathisia. J Clin Psychopharmacol 24 (2004) 618-623
44. Fleischhacker W.W., Rabinowitz J., Kemmler G., Eerdekens M., and Mehnert A. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 187 (2005) 131-136
45. Hofer A., Kemmler G., Eder U., Edlinger M., Hummer M., and Fleischhacker W.W. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 65 (2004) 932-939
46. Galletly C.A., Clark C.R., McFarlane A.C., and Weber D.L. Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res 72 (1997) 161-166
47. Lehman A.F. A quality of life interview for the chronically mentally ill. Eval Program Plann 11 (1988) 51-62
48. Liddle P.F., Barnes T.R., Curson D.A., and Patel M. Depression and the experience of psychological deficits in schizophrenia. Acta Psychiatr Scand 88 (1993) 243-247
49. Bermanzohn P.C., Porto L., Arlow P.B., Pollack S., Stronger R., and Siris S.G. Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes. Schizophr Bull 26 (2000) 517-525
50. Liddle P.F., and Barnes T.R. The subjective experience of deficits in schizophrenia. Compr Psychiatry 29 (1988) 157-164
51. de Haan L., Lavalaye J., van Bruggen M., van Nimwegen L., Booij J., van Amelsvoort T., et al. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry 49 (2004) 290-296
52. Addington D., Addington J., and Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl (1993) 39-44
53. Addington D., Addington J., and Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res 11 (1994) 239-244
54. Rocca P., Bellino S., Calvarese P., Marchiaro L., Patria L., Rasetti R., et al. Depressive and negative symptoms in schizophrenia: different effects on clinical features. Compr Psychiatry 46 (2005) 304-310
55. Siris S.G., Addington D., Azorin J.M., Falloon I.R., Gerlach J., and Hirsch S.R. Depression in schizophrenia: recognition and management in the USA. Schizophr Res 47 (2001) 185-197
56. Fitzgerald P.B., Williams C.L., Corteling N., Filia S.L., Brewer K., Adams A., et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand 103 (2001) 387-392
57. Ruggeri M., Bisoffi G., Fontecedro L., and Warner R. Subjective and objective dimensions of quality of life in psychiatric patients: a factor analytical approach: the South Verona Outcome Project 4. Br J Psychiatry 178 (2001) 268-275
58. Trauer T., Duckmanton R.A., and Chiu E. A study of the quality of life of the severely mentally ill. Int J Soc Psychiatry 44 (1998) 79-91
59. Lobana A., Mattoo S.K., Basu D., and Gupta N. Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatr Scand 104 (2001) 51-55
60. Wehmeier P.M., Kluge M., Schacht A., Helsberg K., and Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res 91 (2007) 178-186
61. Moritz S., Krausz M., Gottwalz E., Lambert M., Perro C., Ganzer S., et al. Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. Psychopathology 33 (2000) 48-51
62. Naber D., and Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 11 Suppl 4 (2001) S391-S396
63. Kim J.H., Kim S.Y., Ahn Y.M., and Kim Y.S. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 301-305
64. Weiden P., Rapkin B., Mott T., Zygmunt A., Goldman D., Horvitz-Lennon M., et al. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull 20 (1994) 297-310
65. Voruganti L.N., and Awad A.G. Personal Evaluation of Transitions in Treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 56 (2002) 37-46